OVIT (OncoVista Innovative Therapies) Goodwill-to-Asset: 0.00 (As of Sep. 2015)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is OncoVista Innovative Therapies Goodwill-to-Asset?

OncoVista Innovative Therapies OVIT Goodwill-to-Asset is 0.00 as of Sep. 2015.

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. OncoVista Innovative Therapies's Goodwill for the quarter that ended in Sep. 2015 was $0.00 Mil. OncoVista Innovative Therapies's Total Assets for the quarter that ended in Sep. 2015 was $0.06 Mil.


OncoVista Innovative Therapies  (OTCPK:OVIT) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


OncoVista Innovative Therapies Goodwill-to-Asset Related Terms


OncoVista Innovative Therapies Goodwill-to-Asset Historical Data

* Premium members only.

The historical data trend for OncoVista Innovative Therapies's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoVista Innovative Therapies Goodwill-to-Asset Chart

OncoVista Innovative Therapies Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Goodwill-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OncoVista Innovative Therapies Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OVIT vs RSPI, HSTC, CAPS: Goodwill-to-Asset Comparison

For the Biotechnology subindustry, OncoVista Innovative Therapies's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoVista Innovative Therapies Goodwill-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoVista Innovative Therapies's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where OncoVista Innovative Therapies's Goodwill-to-Asset falls into.



OncoVista Innovative Therapies Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

OncoVista Innovative Therapies's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2014 is calculated as

Goodwill to Asset (A: Dec. 2014 )=Goodwill/Total Assets
=0/0.013
=

OncoVista Innovative Therapies's Goodwill to Asset Ratio for the quarter that ended in Sep. 2015 is calculated as

Goodwill to Asset (Q: Sep. 2015 )=Goodwill/Total Assets
=0/0.061
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Goodwill-to-Asset →
What does a Goodwill-to-Asset of 0.00 mean?
OncoVista Innovative Therapies (OVIT) has a Goodwill-to-Asset of 0.00 as of Sep. 2015. Goodwill-to-Asset Ratio is the total goodwill from acquisitions divided by total assets. View historical data on OncoVista Innovative Therapies and its competitors.
Is OncoVista Innovative Therapies' Goodwill-to-Asset too high?
OncoVista Innovative Therapies' current Goodwill-to-Asset is 0.00.
How does OncoVista Innovative Therapies' Goodwill-to-Asset compare to RSPI and HSTC?
OncoVista Innovative Therapies' Goodwill-to-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Goodwill-to-Asset for a Biotechnology company?
A good Goodwill-to-Asset depends on the Biotechnology industry context. However, Goodwill-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Goodwill-to-Asset mean?
A high Goodwill-to-Asset can signal that a stock is expensive relative to its fundamentals. Goodwill-to-Asset Ratio is the total goodwill from acquisitions divided by total assets. View historical data on OncoVista Innovative Therapies and its competitors. OncoVista Innovative Therapies's current Goodwill-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoVista Innovative Therapies stock overvalued right now?
OncoVista Innovative Therapies (OVIT) has a current Goodwill-to-Asset of 0.00. The current Goodwill-to-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Goodwill-to-Asset calculated?
Goodwill-to-Asset is calculated from a company's financial statements. For OncoVista Innovative Therapies (OVIT), the current Goodwill-to-Asset is 0.00 as of Sep. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OncoVista Innovative Therapies Business Description

Address 14785 Omicron Drive, Suite 104, San Antonio, TX, USA, 78245
OncoVista Innovative Therapies Inc is a biopharmaceutical company. It is engaged in developing anticancer therapies by utilizing tumor-associated biomarkers.